



Eurofins Medinet adds College of American Pathologists (CAP) accreditation to its Central Laboratory in China

May 25, 2009

As a result of its recent inspection by the College of American Pathologists (CAP), Eurofins Medinet's Central Laboratory in Suzhou, near Shanghai, has now been granted its CAP accreditation. With this accreditation Eurofins Medinet's position as one of the few providers of a wholly-owned global network of central laboratories is even more firmly established, covering the world's key regions of pharmaceutical development: North America, Europe and Asia.

The accreditation requires a rigorous interrogation of the laboratory's facilities, records and quality control systems as well as the qualifications and experience of the personnel who work there. As with the CAP accreditation in Singapore in 2008, laboratory director Dr. Stanley Tam was once again congratulated on the excellence of the services that are offered at this new establishment.

The globally-applied standard operating procedures and quality standards that had already been proven in the other Eurofins Medinet-owned central laboratory facilities were replicated in China, illustrating the power of the Eurofins roll-out model. Furthermore, in addition to the laboratory quality assurance standards of CAP, these standards meet a wide range of pharmaceutical industry regulatory requirements such as the National Glycohemoglobin Standardization Program (NGSP) Level 1 certification.

As more pharmaceutical companies are choosing to conduct clinical trials in China, Eurofins Medinet is one of the few central laboratory services companies to have established a wholly-owned and managed facility in the country. Testing services at this newly built facility commenced in April 2008. The facility provides a full range of safety parameters and has extended its offering by adding a range of specialized capabilities such as HPLC and ELISA.

This addition to the network makes Eurofins Medinet one of the top global central laboratory operators in the world, with 6 wholly-owned laboratories including two in the United States and one each in the Netherlands, France, Singapore and China. The Shanghai facility complements the facility in Singapore and with these new laboratories Eurofins Medinet can offer customers a bespoke package of the highest quality central laboratory services in the Asia-Pacific region and globally alike.

For further information please visit www.eurofinsmedinet.com or www.eurofins.com or contact:

Eurofins Medinet
Sandra Hageman
Bergschot 71
4817 PA Breda
The Netherlands
Phone: +31 76 572 72 72
sandra.hageman@eurofinsmedinet.com

Stanley Tam
Eurofins Medinet Shanghai
No. 10B1 Longshan Road SND
Suzhou, Jiangsu Province
P.R. China
Phone: +86 512 6680 1266

stanley.tam@eurofinsmedinet.com

Investor Relations
Phone: +32-2-769 7383
E-mail: ir@eurofins.com

Notes for the editor:

Eurofins – a global leader in bio-analysis

Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors.

With 8,000 staff in more than 150 laboratories across 30 countries, Eurofins offers a portfolio of over 25,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to providing its customers with high quality services, accurate results in time and, if requested, expert advice by its highly qualified staff.

The Eurofins Group is the world leader in food testing and one of the global market leaders in pharmaceuticals and environmental testing. It intends to pursue its dynamic growth strategy and expand both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the NYSE Euronext Paris (ISIN FR0000038259) and Frankfurt (WKN 910 251) Stock Exchanges (Reuters EUFI.LN, Bloomberg ERF FP, ESF, EUFI.DE).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.